Form 4: Neurocrine Biosciences Executive Eric Benevich Reports Stock Transactions

Chief Commercial Officer Eric Benevich of Neurocrine Biosciences reports the vesting of restricted stock units and subsequent sale of shares under a pre-arranged 10b5-1 trading plan.

Summary

• Eric Benevich, Chief Commercial Officer of Neurocrine Biosciences, filed a Form 4 detailing changes in beneficial ownership.
• On February 8, 2025, 1,860 shares of common stock were acquired through the vesting of restricted stock units (RSUs).
• Also on February 8, 2025, 1,860 shares were disposed of.
• On February 10, 2025, 980 shares of common stock were sold at a weighted average price of $118.3065 per share, with prices ranging from $116.07 to $123.53.
• These transactions were executed under a Rule 10b5-1 trading plan adopted on June 10, 2021.
• Following these transactions, Benevich directly owns 42,799 shares of Neurocrine Biosciences stock.

Sentiment

Score: 6

Explanation: The sentiment is neutral. The document simply reports stock transactions by an executive under a pre-existing trading plan. There's no inherent positive or negative implication.

Industry Context

Executive stock transactions are common and closely monitored, especially in the biopharmaceutical industry, to gauge management's confidence in the company's prospects. Rule 10b5-1 plans are frequently used to allow insiders to sell shares without concerns about insider trading.

Comparison to Industry Standards

• Executive compensation packages often include restricted stock units that vest over time, aligning executive interests with long-term shareholder value.
• The use of Rule 10b5-1 trading plans is a standard practice among corporate executives to manage their stock sales in a compliant manner.
• Comparing Benevich's transactions to those of executives at similar-sized biotech companies (e.g., BioMarin, Vertex) would provide context on the scale and frequency of insider trading activity.

Stakeholder Impact

• The stock sale could have a minor impact on shareholders, potentially creating slight downward pressure on the stock price in the short term.
• The vesting of RSUs is part of the executive's compensation package, aligning their interests with the company's performance.

Key Dates

Keywords

Form 4, Beneficial Ownership, Neurocrine Biosciences, NBIX, Eric Benevich, Restricted Stock Units, Rule 10b5-1 Trading Plan, Stock Sale